TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total number of antibiotic items dispensed per 100 NHS treatment claims
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sample adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of stroke/systemic emboli
Endpoint domain: Mortality/survival
Primary endpoint: Total bleeds
Endpoint domain: Adverse events/effects
Primary endpoint: Raised alanine aminotransferase values
Endpoint domain: Adverse events/effects
Primary endpoint: Inappropriate digoxin level determinations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intensity of propofol injection pain (verbal pain score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer erythrocyte transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduction in the volume of packed erythrocytes transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: higher hematocrit values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: itching severity score at day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foreign body sensation severity score at day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: photophobia severity score at day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in functional task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aura severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favourable therapeutic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year follow-up survival period
Endpoint domain: Mortality/survival
Primary endpoint: Number of circulating P-selectin-positive platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet degranulation in response to iso-thrombin receptor agonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet surface GP IIIa expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum expiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: voluntary peak cough flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Excess Post-exercise Oxygen Consumption (EPOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net changes of free fatty acids (FFAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Net changes of triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Net changes of high-density lipoprotein (HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Five-facet mindfulness questionnaire (FFMQ) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IIEF orgasmic function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confidence scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase of empowerment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in QTc from baseline to end of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTc prolongation ≥60 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTc ≥480 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total diet during the first year of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: on-road driving evaluation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EDSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month confirmed disability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL particle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum HDL cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Concentration (GMC) of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of titers more than 100 mIU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcome at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cognitive outcome at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distribution of attention to facial features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in anxiety, agitation, aggression, and apathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in social communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement in activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: vein graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: food attentional bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interoceptive awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute amplitude of the MEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GBV-C/HGV RNA frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HGV antibodies occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Contact with GBV-C/HGV virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and clinical efficacy of the SurVeil DCB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Autonomic nervous activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HRV (total power, HF, LF, VLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dynamics of mental deterioration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mtDNA damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reactive oxygen species (ROS) generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of mitochondrial membrane potential (ΔΨm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CME presenter feedback scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BIS maintenance within +/- 10 of the target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median absolute performance error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative schizotypy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disorganization dimensions of schizotypy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual function protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sense of first urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time of first urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of first urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevention of postpartum urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time to impending relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index Z scores (BMIZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of bloating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total hospital charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the receiver operating characteristic (ROC) curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on PANSS Subscales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Symptoms and Depression Factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinic attendance rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: revision ACL surgery
Endpoint domain: Mortality/survival
Primary endpoint: Composite end point of death/recurrence
Endpoint domain: Mortality/survival
Primary endpoint: PSA failure-free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CCR5 32 allele
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: duration to onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of neuromuscular relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Mean blood pressure and heart rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comfort and impression of anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood antioxidant and oxidant levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: patient dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapist control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient expressiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of pockets ≥7 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: best sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined total time of each set
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % decrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO(2) during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with life situations
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thiazide Prescribing Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean competence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to start oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: learning outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-reactive insulin antibodies levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chronic superficial gastritis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall IBS‐SSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perceived exercise frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived exercise intensity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: steady-state Cmax of sacubitrilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC0-24h of sacubitrilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: half-life of sacubitrilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Negative urea breath test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total area under the plasma buspirone concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma buspirone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of the total area under the plasma concentration-time curve of 1-PP to that of buspirone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak tricuspid regurgitation velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in peak levels of postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in the risk for dyslipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endothelial cell loss percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term endothelial survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD of weight-bearing bones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: first trimester abortion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Total acquisition cost of milrinone vs dobutamine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DAS-28 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient global assessment of disease activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: therapeutic adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrepancies in self-reported and measured height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrepancies in self-reported and measured weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrepancies in self-reported and measured BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pneumotachometers after disinfections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-oxidation rate of beta cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FEV(1)/PEF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV(1)/FEV(0.5) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained virologic response at post‐treatment week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in apolipoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaccine uptake rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: substance-specific ASSIST scores for marijuana
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: substance-specific ASSIST scores for cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level during venepuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for venepuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean period to improvement of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent diameter stenosis (PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normal baseline reference diameter (DNORM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of vomiting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of postprandial PYY levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of NUCB2/nesfatin-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total piritramide consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized area of hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early objective response (EOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median decrease in paraprotein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of phospho-NOS3 to total NOS3 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Conventional CVD risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in plaque index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rates for vaccine strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulmonary function depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in left ventricle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in intima-medial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean induced corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-catheterization odds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post procedural cTnI level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of gastric pH≤3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of gastric bacteria colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in paraprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in urinary N‐telopeptide of type I collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of rapid symptom return
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in global photoaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median National Institutes of Health Stroke Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MCA recanalization after endovascular treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of subjects with mucosal breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidents of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptance of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total number of demyelinating findings (DF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: occurrence of ≥ 4 new demyelinating findings (DF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical response and parasite elimination efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gametocyte elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of parasitemia and fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheeze affecting activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perceived improvement of breathing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status